Sitemap
- Home
-
Behind the science magazine
- Computational Biology: setting the stage for future wins and new medicines
- Tackling tomorrow’s health challenges today
- How vaccine science can help tackle antimicrobial resistance
- Antibiotic resistance: now’s the time to prevent the next pandemic
- Why we’re introducing Shingles Awareness Week
- Tech for T-cells single cell RNA seq measures shifts in immune cells to pinpoint causes of disease
- How adjuvants boost our immune response
- The 40 year fight against HIV
- How the next generation of immuno-oncology could help us get ahead of cancer
- Getting ahead of infectious diseases with advanced technology
- 1.4 million reasons to get ahead of gynaecologic cancers
- How we're getting ahead of an incurable blood cancer
- Following the science of oxygen to discover solutions for anaemia
- Digital twin: using advanced technology to accelerate vaccine development
- What if remission were the target of lupus care?
- Targeting treatable traits in asthma and other respiratory conditions
- Synthetic Lethality: accelerating precision cancer treatments
- Fresh insights could finally help us tackle RSV
- Combining genetics and tech to double success rates
- AI and ML power better predictions for patient impact
- Could tiny bubbles released from bacteria cells pave the way for new vaccine technology
- Unlocking the power of the immune system to get ahead of hepatitis B
- Time for a change: personalising asthma treatment
- Eosinophils could be holding the missing link between symptoms, diagnosis and treatment
- The logic of biologic medicines: advancing care for people with immune-mediated conditions
- Using new science to get ahead of myelofibrosis - a rare blood cancer
- Getting ahead of COPD exacerbations using new tech could save lives
- Harnessing tumour DNA to detect cancer recurrence earlier
- The ‘tripledemic’ will hit older people hard this winter – but there are things we can all do to reduce the impact
- ‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
- ‘I had never experienced anything like it’: the pain, risks, and first symptoms of shingles every adult should know
- Age-related decline in immunity: why does it matter and what can be done about it?
- ‘We’re not a world of men – it's as simple as that’: how gender diversity in clinical trials improves health outcomes for women
- ‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics
-
Company
- Purpose, strategy and culture
- Outstanding people
- GSK at a glance
- History and heritage
-
Board of directors and leadership team
- Dame Emma Walmsley
- Iain Mackay
- Dr Hal Barron
- Diana Conrad
- James Ford
- Sally Jackson
- Luke Miels
- David Redfern
- Shobie Ramakrishnan
- Regis Simard
- Phil Thomson
- Deborah Waterhouse
- Tony Wood
- Sir Jonathan Symonds CBE
- Charles Bancroft
- Dr Anne Beal
- Dr Harry (Hal) C Dietz
- Dr Laurie Glimcher
- Dr Jesse Goodman
- Urs Rohner
- Dr Vishal Sikka
- Elizabeth (Liz) McKee Anderson
- Julie Brown
- Board information
- Governance
- Policy positions
- Codes, standards and reports
-
Locations
- Albania
- Algeria
- Argentina
- Austria
- Bangladesh
- Belarus
- Bosnia and Herzegovina
- Bulgaria
- Cambodia
- Caribbean Islands
- Chile
- Colombia
- Costa Rica
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Dominican Republic
- Ecuador
- Estonia
- Egypt
- El Salvador
- Finland
- Georgia
- Greece
- Guatemala
- Honduras
- Hong Kong and Macau
- Hungary
- Indonesia
- Ireland
- Israel
- Jamaica
- Kazakhstan
- Kenya
- Latvia
- Lebanon
- Lithuania
- North Macedonia
- Malaysia
- Malta
- Mauritius
- Mexico
- Moldova
- Montenegro
- Morocco
- Myanmar
- Netherlands
- New Zealand
- Nicaragua
- Norway
- Panamá
- Peru
- Philippines
- Romania
- Saudi Arabia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- Sri Lanka
- Sweden
- Switzerland
- Thailand
- Trinidad & Tobago
- Tunisia
- Ukraine
- United Arab Emirates
- Uruguay
- Uzbekistan
- Venezuela
- Vietnam
- United Kingdom
- Innovation
- Products
- Responsibility
- Investors
- Media
- Careers
- Cookie policy
